Stock info Alimera Sciences | Filter  Basic-Info

Alimera Sciences

The past year was a good year for Alimera Sciences investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Alimera Sciences, the stock lost around 62 percent. The period between August 2011 and August 2016 was a loss-making period for the investors. The stock lost on average 11 percent. Alimera Sciences's net results between 2011 and 2015 were quite unstable and moved between -22,52 million dollars and -30,65 million dollars.

Alimera Sciences's headquarter is located in Alpharetta. Alimera Sciences is mostly active in the pharmaceutical sector. Mr. Charles Daniel Myers is operating by ' CEO. The CFO of the company is Mr. Richard S. Eiswirth Jr.. The global pharmaceutical companies gained over the past 10 years on average 75 percent. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

Over the past 5 years the American company paid out dividends.

Alimera Sciences' balance mostly consists of equity

Last year the balance sheet of the American company was worth 70,48 million dollars. 44,16 million dollars (62,66 percent of the total balance sheet) was financed by debt. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio -8. So the stock' value was -8 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

The pharmaceutical company's market capitalization (the number of shares outstanding times the market value) equaled around 108,9 million dollars. At the end of 2015 the American company had around 44,45 million stocks listed on the stock exchange(s).

At this page you find all Alimera Sciences's financial reports. More information about Alimera Sciences can be found it's website. .